CORONA Remedies Limited (NSE:CORONA)

Market Cap	136.76B
Revenue (ttm)	14.79B +19.2%
Net Income	1.99B +25.0%
EPS	32.55 +25.1%
Shares Out	61.16M
PE Ratio	68.70
Forward PE	52.89
Dividend	10.00 (0.49%)
Ex-Dividend Date	Jun 19, 2026

Volume	155,193
Open	2,225.00
Previous Close	2,200.80
Day's Range	2,181.50 - 2,246.70
52-Week Range	1,336.60 - 2,270.10
Beta	n/a
Analysts	Strong Buy
Price Target	2,304.67 (+3.44%)
Earnings Date	Nov 14, 2026

About CORONA Remedies

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2004
• Employees: 5,153
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: CORONA

Financial Performance

In fiscal year 2026, CORONA Remedies's revenue was 14.03 billion, an increase of 17.28% compared to the previous year's 11.96 billion. Earnings were 1.85 billion, an increase of 23.88%.

Analyst Summary

According to 3 analysts, the average rating for CORONA stock is "Strong Buy." The 12-month stock price target is ₹2,305, which is an increase of 3.44% from the latest price.

Price Target

₹2,305

(3.44% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 14, 2026

Data Sources Report a data error